Why Should Regulators Consider Using Patient Preferences in Benefit-risk Assessment? Janine A. van TilMaarten J. IJzerman Editorial 28 November 2013 Pages: 1 - 4
Use of Proton Pump Inhibitors for the Provision of Stress Ulcer Prophylaxis: Clinical and Economic Consequences Jeffrey F. BarlettaDavid A. Sclar Review Article 25 November 2013 Pages: 5 - 13
Review of Models Used in Economic Analyses of New Oral Treatments for Type 2 Diabetes Mellitus Carl V. AscheStephen E. HipplerDean T. Eurich Review Article 20 December 2013 Pages: 15 - 27
Cost Effectiveness of the New Pneumococcal Vaccines: A Systematic Review of European Studies Katelijne van de VoorenSilvy DurantiLivio Garattini Systematic Review 28 November 2013 Pages: 29 - 45
The Impact of Structural Uncertainty on Cost-Effectiveness Models for Adjuvant Endocrine Breast Cancer Treatments: the Need for Disease-Specific Model Standardization and Improved Guidance Gerardus W. J. FrederixJohan G. C. van HasseltJohan L. Severens Original Research Article 22 November 2013 Pages: 47 - 61
Comparative and Cost Effectiveness of Treatment Modalities for Hepatocellular Carcinoma in SEER-Medicare Fadia T. ShayaIan M. BreunigNader Hanna Original Research Article 29 November 2013 Pages: 63 - 74
The Value of a QALY: Individual Willingness to Pay for Health Gains Under Risk Ana BobinacJob van ExelWerner B. F. Brouwer Original Research Article 29 November 2013 Pages: 75 - 86
Treating Idiopathic Pulmonary Fibrosis with the Addition of Co-Trimoxazole: An Economic Evaluation Alongside a Randomised Controlled Trial Edward C. F. WilsonLudmila ShulginaAndrew M. Wilson Original Research Article 04 December 2013 Pages: 87 - 99
